171 related articles for article (PubMed ID: 31539199)
1. An analysis of the false negative rate of minimal residual disease measurement by multiparameter flow cytometry in multiple myeloma.
Austin M; O'Connor S; Morilla R; Pawlyn C; Kaiser MF; Boyd KD
Int J Lab Hematol; 2020 Apr; 42(2):e65-e67. PubMed ID: 31539199
[No Abstract] [Full Text] [Related]
2. Aggressive and extramedullary plasma cell myeloma evade bone marrow flow cytometric minimal residual disease detection.
Came N; Nguyen V; Westerman D; Harrison S
Br J Haematol; 2016 Jun; 173(6):947-9. PubMed ID: 26456706
[No Abstract] [Full Text] [Related]
3. Introduction to multiple myeloma special issue: The flow cytometric detection of minimal residual disease.
Preffer FI; Yuan CM; Lin P; Stetler-Stevenson M; Marti GE
Cytometry B Clin Cytom; 2016 Jan; 90(1):9-10. PubMed ID: 26780351
[No Abstract] [Full Text] [Related]
4. A single-tube six-colour flow cytometry screening assay for the detection of minimal residual disease in myeloma.
de Tute RM; Jack AS; Child JA; Morgan GJ; Owen RG; Rawstron AC
Leukemia; 2007 Sep; 21(9):2046-9. PubMed ID: 17657223
[No Abstract] [Full Text] [Related]
5. Comparison of minimal residual disease detection in multiple myeloma between the DuraClone and EuroFlow methods.
Yoroidaka T; Narita K; Takamatsu H; Fujisawa M; Nakao S; Matsue K
Sci Rep; 2021 May; 11(1):11218. PubMed ID: 34045494
[TBL] [Abstract][Full Text] [Related]
6. Assessment of response to therapy in multiple myeloma by multiparameter flow cytometry. Usefulness of an eight-color single tube with monoclonal antibodies in dried formulation.
Carulli G; Tarasco A; Sammuri P; Ottaviano V; Domenichini C; Ciancia EM; Petrini M
Clin Ter; 2019; 170(5):e352-e356. PubMed ID: 31612192
[TBL] [Abstract][Full Text] [Related]
7. Single-Tube 10-Fluorochrome Analysis for Efficient Flow Cytometric Evaluation of Minimal Residual Disease in Plasma Cell Myeloma.
Royston DJ; Gao Q; Nguyen N; Maslak P; Dogan A; Roshal M
Am J Clin Pathol; 2016 Jul; 146(1):41-9. PubMed ID: 27402608
[TBL] [Abstract][Full Text] [Related]
8. Go with the flow for monitoring response in myeloma with minimal residual disease.
Mason KD; Juneja S
Leuk Lymphoma; 2008 Feb; 49(2):177-8. PubMed ID: 18231901
[No Abstract] [Full Text] [Related]
9. Minimal residual disease testing in multiple myeloma by flow cytometry: major heterogeneity.
Flanders A; Stetler-Stevenson M; Landgren O
Blood; 2013 Aug; 122(6):1088-9. PubMed ID: 23929839
[No Abstract] [Full Text] [Related]
10. Diagnosis of Plasma Cell Dyscrasias and Monitoring of Minimal Residual Disease by Multiparametric Flow Cytometry.
Soh KT; Tario JD; Wallace PK
Clin Lab Med; 2017 Dec; 37(4):821-853. PubMed ID: 29128071
[TBL] [Abstract][Full Text] [Related]
11. Minimal Residual Disease Detection by Flow Cytometry in Multiple Myeloma: Why and How?
Roshal M
Semin Hematol; 2018 Jan; 55(1):4-12. PubMed ID: 29759152
[TBL] [Abstract][Full Text] [Related]
12. Immunophenotypic Heterogeneity of Polytypic Plasma Cells and the Impact on Myeloma Minimal Residual Disease Detection by Multiparameter Flow Cytometry.
Schouweiler KE; Karandikar NJ; Holman CJ
Cytometry B Clin Cytom; 2019 Jul; 96(4):310-318. PubMed ID: 31140731
[TBL] [Abstract][Full Text] [Related]
13. Blood monitoring of circulating tumor plasma cells by next generation flow in multiple myeloma after therapy.
Sanoja-Flores L; Flores-Montero J; Puig N; Contreras-Sanfeliciano T; Pontes R; Corral-Mateos A; García-Sánchez O; Díez-Campelo M; Pessoa de Magalhães RJ; García-Martín L; Alonso-Alonso JM; García-Mateo A; Aguilar-Franco C; Labrador J; Barez-García A; Maiolino A; Paiva B; San Miguel J; Sobral da Costa E; González M; Mateos MV; Durie B; van Dongen JJM; Orfao A
Blood; 2019 Dec; 134(24):2218-2222. PubMed ID: 31697808
[No Abstract] [Full Text] [Related]
14. Minimal residual disease monitoring in multiple myeloma: flow cytometry is the method of choice.
Owen RG; Rawstron AC
Br J Haematol; 2005 Mar; 128(5):732-3; author reply 733-4. PubMed ID: 15725097
[No Abstract] [Full Text] [Related]
15. Minimal residual disease in multiple myeloma: why, when, where.
Yee AJ; Raje N
Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):37-45. PubMed ID: 34889430
[TBL] [Abstract][Full Text] [Related]
16. Automated and simplified identification of normal and abnormal plasma cells in Multiple Myeloma by flow cytometry.
Alaterre E; Raimbault S; Garcia JM; Rème T; Requirand G; Klein B; Moreaux J
Cytometry B Clin Cytom; 2018 May; 94(3):484-492. PubMed ID: 28865180
[TBL] [Abstract][Full Text] [Related]
17. Comparison of cross-platform flow cytometry minimal residual disease evaluation in multiple myeloma using a common antibody combination and analysis strategy.
Mathis S; Chapuis N; Borgeot J; Maynadié M; Fontenay M; Béné MC; Guy J; Bardet V
Cytometry B Clin Cytom; 2015 Mar; 88(2):101-9. PubMed ID: 25399680
[TBL] [Abstract][Full Text] [Related]
18. Minimal residual disease detection of myeloma using sequencing of immunoglobulin heavy chain gene VDJ regions.
Ho C; Arcila ME
Semin Hematol; 2018 Jan; 55(1):13-18. PubMed ID: 29759147
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of measurable residual disease in multiple myeloma by multiparametric flow cytometry: Current paradigm, guidelines, and future applications.
Soh KT; Wallace PK
Int J Lab Hematol; 2021 Jul; 43 Suppl 1():43-53. PubMed ID: 34288449
[TBL] [Abstract][Full Text] [Related]
20. Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma.
Flores-Montero J; de Tute R; Paiva B; Perez JJ; Böttcher S; Wind H; Sanoja L; Puig N; Lecrevisse Q; Vidriales MB; van Dongen JJ; Orfao A
Cytometry B Clin Cytom; 2016 Jan; 90(1):61-72. PubMed ID: 26100534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]